Tamoxifen-Resistant Variant of ZR-75-1 Breast Cancer Cells
Author Information
Author(s): H.W. van den Berg, M. Lynch, J. Martin, J. Nelson, G.R. Dickson, A.D. Crockard
Primary Institution: The Queen's University of Belfast
Hypothesis
What are the characteristics and stability of a tamoxifen-resistant variant of the ZR-75-1 human breast cancer cell line?
Conclusion
The ZR-75-9al variant of ZR-75-1 cells shows resistance to tamoxifen and has lost both estrogen and progesterone receptors.
Supporting Evidence
- ZR-75-9al cells lost both estrogen and progesterone receptors after prolonged tamoxifen exposure.
- The resistant phenotype was stable in the presence of tamoxifen but not in drug-free conditions.
- ZR-75-9al cells showed morphological changes consistent with a less differentiated phenotype.
Takeaway
Researchers created a new type of breast cancer cell that doesn't respond to tamoxifen, a common treatment, and they found it behaves differently than the original cells.
Methodology
Cells were cultured in increasing concentrations of tamoxifen and assessed for receptor expression and cell cycle distribution.
Limitations
The resistant phenotype was not stable in drug-free conditions, indicating potential variability in resistance.
Want to read the original?
Access the complete publication on the publisher's website